BioWorld Asia

March 27, 2002

View Archived Issues

Amrad’s Stock Falls On Poor Phase II Results For Emfilermin

New Gene Inhibition Technique Aims To Hasten Gene Analysis

Schering To Purchase Collateral For $140M In Stock Exchange

Millennium, Compugen In Deal For Protein Pathway Software

Cyclacel, University Of Edinburgh Form Drug Design Collaboration

Avidex Platform Creates TCRs; Company Planning Partnerships

U.S. Research Foundation Backs Swedish Stem Cell Program

ReGen’s Phase IIa Interim Data Not Significant In Alzheimer’s

Other News To Note

Vernalis Seeks Second Nasdaq Listing, Reports Profitability

J&J Buying Tibotec-Virco For $320 In Cash And Debt

PARIS Johnson & Johnson signed a definitive agreement to acquire all of the assets of Tibotec-Virco NV for $320 million in cash and debt. (BioWorld International) Read More

Today's news in brief

BioWorld

BioWorld briefs for June 23, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

Nankai University and Accendatech present new majusculamide D derivatives

BioWorld Science

Scientists from Nankai University Tianjin and Accendatech Technology Co. Ltd. have identified a majusculamide D derivative found to be useful for the treatment of...